id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2013-D-1464-0001,FDA,FDA-2013-D-1464,Draft Guidance for Industry on Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application; Availability,Notice,Notice of Availability,2013-12-05T05:00:00Z,2013,12,2013-12-05T05:00:00Z,2014-03-06T04:59:59Z,2014-03-06T02:01:21Z,2013-29081,0,0,09000064814a9ea0
FDA-2013-D-1464-0002,FDA,FDA-2013-D-1464,Guidance for Industry; Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA,Other,Guidance,2013-12-04T05:00:00Z,2013,12,2013-12-04T05:00:00Z,,2024-11-12T05:24:47Z,,1,0,09000064814aa14c